Cite
HARVARD Citation
Weniger, M. et al. (2020). Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is feasible and lead to a similar oncological outcome compared to non-aged patients – Results of the RESPECT-Study. Surgical oncology. pp. 285-297. [Online].